CLINICAL EVALUATION OF CEFMENOXIME IN THE INTERNAL MEDICINE, WITH SPECIAL REFERENCE TO INFECTION ASSOCIATED WITH HEMATOLOGICAL DISORDERS

Abstract

Clinical evaluation of cefmenoxime (CMX, Bestcall®) was examined in the infection associated with hematological disorders, respiratory tract and other disorders. Clinical effectiveness for severe infection of hematological disorders was 47.4% in good and 84.2% in fair response, however, in the respiratory tract infections, 89.7% in good responce was obtained. Opportunistic infection due to Gram-negative bacilli are often experienced in patients with hematological disorders. It was discussed that CMX would be a good therapeutic agent against infectious diseases associated with hematological disorders because it's antibacterial spectrum would be parallel to pathogens of such disorders.